This article was originally published in Pharmaceutical Approvals Monthly
FDA Gastrointestinal Drugs Advisory Committee will meet June 26 in Gaithersburg, Md. to discuss NDA 21-200 for Novartis' Zelmac (tegaserod) for the treatment of abdominal pain and discomfort, bloating and altered bowel function in patients with irritable bowel syndrom
You may also be interested in...
No device-related warning letters were released by the US FDA the week of 22 September.
Created in 2016 by consolidating five European companies, CNS specialist Neuraxpharm is changing hands, with funds advised by global investor Permira paying an undisclosed sum to take control of a business boasting annual revenues of around €460m ($541m) and more than 115 CNS molecules at its disposal.
Following Perrigo’s announcement of a recall of its generic albuterol inhalers in the US, the FDA has commented on the move and has revealed that thousands of complaints have been received over the clogging problem.